Clinical trials
Rare Diseases trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Unknown status | 4 |
| Recruiting | 4 |
| Terminated | 2 |
| Active, not recruiting | 2 |
| Withdrawn | 1 |
| Enrolling by invitation | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Center for Research Resources (NCRR) | 4 |
| Friedreich's Ataxia Research Alliance | 2 |
| Novartis Pharmaceuticals | 2 |
| REGENXBIO Inc. | 2 |
| Gemma Biotherapeutics | 1 |
| Hanns Lochmuller | 1 |
| Holland Bloorview Kids Rehabilitation Hospital | 1 |
| Kyowa Kirin Co., Ltd. | 1 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| NightstaRx Ltd, a Biogen Company | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Rare Diseases | 22 |
| Genetic Diseases, Inborn | 4 |
| Communicable Diseases | 3 |
| Immune System Diseases | 3 |
| Metabolic Diseases | 3 |
| Neurodegenerative Diseases | 3 |
| Neurologic Manifestations | 3 |
| Atherosclerosis | 2 |
| Cardiovascular Diseases | 2 |
| Friedreich Ataxia | 2 |
Trials
Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.